# RESORCE (NCT01774344)

> Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

No report yet. It can be ordered.

- Drugs tested: regorafenib
- Indication: hepatocellular carcinoma progressing on sorafenib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01774344
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Carcinoma, Hepatocellular
- Interventions: Regorafenib (Stivarga, BAY73-4506); Placebo
- Enrollment: 573
- Primary outcome: Overall Survival (OS)

## Indexed commentary on RESORCE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=resorce-nct01774344

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01774344", "email": "<work email>"}; the inbox owner confirms by the emailed link.